WHAT CHANGED?

The developments that change how the story should be understood.

Research. Regulatory. Market.

Peptide science and commercialization move quickly. This desk tracks developments that materially change the evidence, regulatory context or market around a compound—and separates the update itself from what people may be tempted to conclude from it.

Our format

What Changed → What It Means → What It Doesn’t Mean

Every update should make the interpretation clearer, not simply make the headline louder.

01 / LATEST

Recent developments worth understanding.

Each item is assigned to one of three lanes: Research, Regulatory or Market.

REGULATORY · JULY 2026

FDA advisory committee reviews four high-interest peptide substances.

What Changed: FDA’s Pharmacy Compounding Advisory Committee considered BPC-157-related substances, KPV, TB-500 and MOTS-c for possible inclusion on the 503A Bulks List.

What It Means: These compounds are receiving formal regulatory scrutiny around compounding.

What It Doesn’t Mean: Advisory committee review is not FDA drug approval and does not establish that the compounds are safe or effective treatments.

REGULATORY · 2026

Retatrutide’s compounding status is unusually clear.

What Changed: FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law and are not components of FDA-approved drugs.

What It Means: The commercial conversation around “compounded retatrutide” is not simply an early-access version of an approved medicine.

What It Doesn’t Mean: This does not erase the clinical trial evidence for retatrutide; it separates investigational efficacy data from regulatory status.

MARKET · AUGUST 2026

FDA warning-letter activity reaches peptide sellers.

What Changed: FDA issued a warning letter after reviewing a peptide seller’s website, identifying products marketed as retatrutide, elamipretide, tesamorelin, bremelanotide and others as unapproved new drugs under the conditions described in the letter.

What It Means: Enforcement risk is part of the peptide market story, especially when products are marketed for human use.

What It Doesn’t Mean: A warning letter about a seller does not rewrite the evidence or approval status of an appropriately approved branded drug product.

REGULATORY · JULY 2026

FDA updates its scientific approach to generic peptide products.

What Changed: FDA published 17 revised draft product-specific guidances for peptide products, including semaglutide, liraglutide, teriparatide and calcitonin products.

What It Means: Peptides are increasingly part of mature pharmaceutical regulation—not merely an experimental biohacking category.

What It Doesn’t Mean: Guidance for approved peptide drug categories does not confer legitimacy or approval on unrelated research-market peptides.

02 / THREE LANES

Not every change changes the same thing.

ResearchNew trials, peer-reviewed studies, endpoints, replication, failures and evidence that changes what we know.

RegulatoryApprovals, labels, FDA actions, advisory proceedings, compounding policy and other changes to legal or regulatory context.

MarketEnforcement, commercialization, platform behavior, payment, supply, business models and other forces shaping access and attention.

03 / WHY THIS MATTERS

A headline can change without the evidence changing.

The same compound can simultaneously have promising trial data, no approved indication, strong community demand and a rapidly changing commercial market.

That is why we separate the lanes. A regulatory event should not be presented as a clinical result. A company announcement should not be treated like peer-reviewed evidence. A market enforcement action should not be confused with a scientific verdict.

04 / THE WATCHLIST

Stories with the potential to move the Index.

CLINICAL DEVELOPMENT

Retatrutide

Phase 3 development makes this one of the most consequential evidence stories in metabolic medicine.

Follow Retatrutide →

COMPOUNDING

BPC-157 · KPV · TB-500 · MOTS-c

Regulatory review matters because community adoption has moved far ahead of conventional drug-development evidence for several of these compounds.

MITOCHONDRIAL MEDICINE

Elamipretide

FDA approval in Barth syndrome creates a valuable case study in the difference between a validated narrow indication and broad biohacking extrapolation.

Follow SS-31 →

COMMUNITY

Community Pulse

Watch what people are discussing before assuming the conversation reflects the evidence.

Open Community Pulse →

05 / EDITORIAL STANDARD

What qualifies as “changed”?

We prioritize developments that materially change evidence maturity, regulatory status, safety context, commercialization or the interpretation of a major claim.

Primary sources firstRegulators, trial registries, peer-reviewed papers and original company disclosures are preferred over summaries.

Date everythingA living intelligence product is only useful when readers can see when the underlying fact changed.

Separate source typesPeer-reviewed research, regulator statements and company topline announcements are not equivalent evidence.

Correct the recordWhen new information changes an Index profile, the profile should change with it.

06 / KEEP READING

Move from the update to the underlying evidence.

EVIDENCE

The Science

See how human, preclinical and mechanistic evidence are separated.

Explore The Science →

REFERENCE

The Peptide Index

Use the Index to see the current evidence and regulatory snapshot for each compound.

Open the Index →

COMMUNITY

Community Pulse

Compare what changed in the evidence with what is changing in public discussion.

Open Community Pulse →

FUTURE

What’s Next

Explore the technologies and therapeutic directions moving toward the next generation of optimization.

Explore What’s Next →

Editorial note: BIOHACKING. EVOLVED. is an educational publication, not a medical provider. What Changed? reports research, regulatory and market developments and does not provide diagnosis, dosing, sourcing or treatment guidance.